Major pharmaceutical companies, including Teva Pharmaceutical Industries Limited, Sandoz Group, and Aurobindo Pharma, are opposing states' efforts to move antitrust lawsuits alleging price-fixing out of the Eastern District of Pennsylvania. The companies argue that transferring cases could lead to chaos and duplicity. The litigation, which began in 2016, involves claims against numerous generic drug manufacturers. A new law, the Venue Act, allows states to choose their preferred jurisdictions for antitrust cases, which has already impacted other cases, such as one involving Google.